 "Dr Reddy's launches Plaquenil's generic version in US after USFDA clearance")
Dr Reddy's Laboratories on Wednesday announced the launch of generic version of Plaquenil, used to treat malaria, lupus erythematosus, and rheumatoid arthritis, in the US.
The launch follows approval of Hydroxychloroquine Sulfate tablets, a therapeutic equivalent generic version of Plaquenil, by the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.
Quoting IMS Health data, Dr Reddy's Laboratories, the Plaquenil brand and generic had US sales of approximately $215 million for the most recent twelve months ending in May 2018.
Dr Reddy's said its product Hydroxychloroquine Sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil is a trademark of Concordia International Corp.
Shares of Dr Reddy's Laboratories were trading at Rs 2,293.95 apiece, down 1.11 per cent from the previous close on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app